Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Andrea Botticelli
Institution:
Sapienza University of Rome
Observed institution:
Sapienza University of Rome
ORCID:
0000-0002-6425-9893
Observed ORCID:
0000-0002-6425-9893
OpenAlex ID:
A5133288955
Long-term responders to sacituzumab govitecan in metastatic triple-negative breast cancer: Real-world outcomes and predictors from a multicenter Italian cohort.
2026
·
Roberta Caputo
, Giuseppe Buono
, et al.
·
Journal of Clinical Oncology
·
1
Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2− breast cancer patients with bone metastases
2026
·
Roberta Scafetta
, Marco Donato
, et al.
·
The Oncologist
·
1
Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study
2026
·
Davide Massa
, Theodoros Foukakis
, et al.
·
Nature Communications
PDF
Prognostic impact of tumor recurrence dynamics in patients with HR+/HER2- advanced breast cancer treated with ET+CDK4/6i: Results from the multicenter, Italian study PALMARES-2.
2026
·
Claudio Vernieri
, Roberta Caputo
, et al.
·
Journal of Clinical Oncology
Effectiveness of first-line ET+CDK4/6i continuation beyond disease progression in a large cohort of patients with HR+/HER2− advanced breast cancer: Results from the multicenter, real-world, Italian study PALMARES-2.
2026
·
Claudio Vernieri
, Roberta Caputo
, et al.
·
Journal of Clinical Oncology
Genome-wide biomarker analysis across the full spectrum of HER2-expressing breast cancers to reveal a clonal chromosome 17 imbalance defining unfavourable HER2-low disease
2026
·
Sara Erika Bellomo
, Enrico Berrino
, et al.
·
Biomarker Research
Real-world outcomes of immunotherapy ± chemotherapy in older patients with head and neck cancer. A sub-analysis of the REALKEY Study
2026
·
Matteo Carpani
, Luigi Lorini
, et al.
·
Radiotherapy and Oncology
REALKEY study: patient-reported outcomes in recurrent/metastatic head and neck cancer treated with first-line immunotherapy +/- chemotherapy
2026
·
Sandra Llop
, Álvaro Garcia Bauto
, et al.
·
Radiotherapy and Oncology
Second-line treatment outcomes in immune-experienced recurrent/metastatic HNSCC: results from the REALKEY study
2026
·
Armando Di Bello
, Luigi Lorini
, et al.
·
Radiotherapy and Oncology
Figure S1 from ESR1-Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer
2026
·
Francesca Bonechi
, Marina Bacci
, et al.
Show more works
View as search
Works count:
10
Citation count:
2
H-index:
1
I10-index:
Year
Topic
Type